- Report
- July 2026
- 246 Pages
Global
From €7263EUR$7,990USD£6,245GBP
- Report
- July 2026
- 200 Pages
Global
From €7263EUR$7,990USD£6,245GBP
- Report
- July 2026
- 200 Pages
Global
From €7263EUR$7,990USD£6,245GBP
- Report
- July 2026
- 200 Pages
Global
From €7263EUR$7,990USD£6,245GBP
- Report
- February 2026
- 150 Pages
Global
From €3409EUR$3,750USD£2,931GBP
- Report
- January 2026
- 280 Pages
Global
From €2727EUR$3,000USD£2,345GBP
- Report
- January 2026
- 280 Pages
Global
From €2727EUR$3,000USD£2,345GBP
- Report
- November 2025
- 150 Pages
Global
From €3409EUR$3,750USD£2,931GBP
- Report
- November 2025
- 150 Pages
Global
From €3409EUR$3,750USD£2,931GBP
- Report
- April 2026
- 136 Pages
Global
From €2726EUR$2,999USD£2,344GBP
€3635EUR$3,999USD£3,125GBP
- Report
- April 2026
- 149 Pages
Global
From €2726EUR$2,999USD£2,344GBP
€3635EUR$3,999USD£3,125GBP
- Report
- August 2026
- 187 Pages
Global
From €4318EUR$4,750USD£3,712GBP
- Report
- August 2026
- 130 Pages
Global
From €4318EUR$4,750USD£3,712GBP
- Report
- January 2026
- 131 Pages
Global
From €4318EUR$4,750USD£3,712GBP
- Report
- January 2026
- 110 Pages
Global
From €4318EUR$4,750USD£3,712GBP
- Report
- May 2026
- 185 Pages
Global
From €4090EUR$4,500USD£3,517GBP
- Report
- August 2026
- 123 Pages
Global
From €4318EUR$4,750USD£3,712GBP
- Report
- August 2026
- 146 Pages
Global
From €4318EUR$4,750USD£3,712GBP
- Report
- August 2026
- 100 Pages
Global
From €4318EUR$4,750USD£3,712GBP
- Report
- August 2026
- 134 Pages
Global
From €4318EUR$4,750USD£3,712GBP

Macular Degeneration is a condition that affects the central part of the retina, known as the macula, which is responsible for sharp, central vision. It is the leading cause of vision loss in people over the age of 50. Optical treatments for Macular Degeneration include laser photocoagulation, photodynamic therapy, and anti-VEGF injections. Laser photocoagulation is used to reduce the risk of further vision loss by sealing off leaking blood vessels in the macula. Photodynamic therapy is used to reduce the growth of abnormal blood vessels in the macula. Anti-VEGF injections are used to reduce the growth of abnormal blood vessels and improve vision.
Companies in the Macular Degeneration market include Novartis, Regeneron, Allergan, Genentech, and Roche. Show Less Read more